ArticleBlood research2026
Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma. The non-germinal center B-cell-like (non-GCB) subtype is associated with a poor prognosis and reduced response rates to rituximab cyclophosphamide-doxorubicin-vincristin-prednisone (R-CHOP) therapy. Resistance may involve cluster of differentiation 79B (CD79B)-driven B-cell receptor (BCR)/nuclear factor kappa B activation, microtubule-associated protein 1 light chain 3 (LC3)-mediated autophagy, and telomerase reverse transcriptase (TERT)-related survival signaling. The interrelationships between these markers and their associations with therapeutic responses remain unclear. This study evaluated the association between CD79B, LC3, and TERT expression and response to R-CHOP in non-GCB DLBCL.
methodsThis analytical case-control study included 58 paraffin-embedded samples from patients with non-GCB DLBCL diagnosed at the Dr. Hasan Sadikin General Hospital, Bandung, Indonesia (2017-2023). Tumor characteristics were assessed using immunohistochemical staining for CD79B, LC3, and TERT. Expression levels were evaluated semi-quantitatively based on staining intensity and the proportion of positive tumor cells. Treatment responses were categorized as response (complete/partial) or non-response (stable/progressive). Statistical analyses were performed using the chi-square test, Fisher's exact test, and binary logistic regression, with significance defined as p < 0.05.
resultsTERT, CD79B, and LC3 expression was detected in 53.4%, 55.2%, and 62.1% of the cases, respectively. Among non-responsive patients, TERT and LC3 expression rates were 62.1% and 69.0% (p > 0.05), respectively. CD79B expression was significantly associated with non-response (p = 0.002). Moreover, multivariate analysis identified positive CD79B expression as an independent predictor of non-response to R-CHOP therapy (OR = 9.72).
conclusionCD79B expression was independently associated with a poor response to R-CHOP therapy in non-GCB DLBCL. The positive association between TERT and LC3 suggests the presence of additional metabolic adaptation mechanisms supporting tumor survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.